Home › NCT05697328
Barotrauma in Hyperbaric Oxygen Therapy
Recruiting
Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * New patient requiring HBOT (either inpatient or outpatient) * Age greater than or equal to 18 years and less than 80 years * Fluent in English * Full decision capacity * Able and medically cleared to swallow a pill Exclusion Criteria: * Enrollment would delay hyperbaric therapy more than 30 minutes in patients with emergent indications (example: Central Retinal Arterial Occlusion, Carbon Monoxide, Air Gas Embolism) * Contraindication to pseudoephedrine (monoamine oxidase inhibitors (MAOI) use, pregnancy, glaucoma, heart disease, allergy to drug class) * Systolic Blood Pressure \>160 * Diastolic Blood Pressure \> 90 * Heart Rate \>100 * Decongestant/antihistamine/pseudoephedrine/nasal steroid/oxymetazoline use within 12 hours. * Prisoner * Intubated * Unable to swallow oral medications
About the study
The purpose of this research is to study whether the use of pseudoephedrine can help prevent middle ear trauma during HBOT. Pseudoephedrine is an approved drug that is used for temporary relief of nasal or sinus pain and pressure.
What is being tested
- Pseudoephedrine Pill (drug)
- Placebo (drug)
Sponsor: John Muir Health · Participants: 90 · Started: Jan 31, 2023
Contact the study team
- Jacinta Showers, RN · Phone: 9259473212
- Todd Kessinger, MD, MD · Phone: 9259473212
Official record on ClinicalTrials.gov — NCT05697328
Locations in the U.S.
| California | John Muir Health, Walnut Creek |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.